Literature DB >> 7536946

Therapeutic effect of percutaneous ethanol injection on small hepatocellular carcinoma: evaluation with CT.

M Ebara1, K Kita, N Sugiura, M Yoshikawa, H Fukuda, M Ohto, F Kondo, Y Kondo.   

Abstract

PURPOSE: To evaluate the therapeutic effect of percutaneous ethanol injection (PEI) on small hepatocellular carcinoma (HCC) with computed tomography (CT).
MATERIALS AND METHODS: Sixty-seven patients with histologically proved HCC 3 cm or less in diameter underwent PEI. The patients were regularly followed up with sonography and contrast material-enhanced CT for more than 1 year (range, 12-96 months). The CT findings were evaluated for three tumor types distinguished on the basis of their appearance relative to that of the surrounding liver parenchyma: type 1 = hyperattenuating at the early phase (n = 39), type 2 = iso- or hypoattenuating at the early phase and hypoattenuating at the late phase (n = 18), and type 3 = isoattenuating (not detected) at both the early and late phases (n = 10).
RESULTS: After PEI, a necrotic area of HCC and the surrounding liver parenchyma was characterized as hypoattenuating at both early and late phases of contrast-enhanced CT, regardless of the type. When an HCC appeared to be completely necrotic within 3 months after PEI, this status was retained until the latest observation in all but three cases.
CONCLUSION: Contrast-enhanced CT can correctly depict PEI-induced necrosis in HCC and is reliable for evaluating the therapeutic effect of PEI.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536946     DOI: 10.1148/radiology.195.2.7536946

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

Review 1.  Ethanol injection for the treatment of hepatic tumours.

Authors:  C Bartolozzi; R Lencioni
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 2.  Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis.

Authors:  Lili Gu; Huiling Liu; Linlin Fan; Yuanjun Lv; Zhuang Cui; Yan Luo; Yuanyuan Liu; Guang Li; Changping Li; Jun Ma
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

3.  Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion.

Authors:  Yukihiro Koike; Haruhiko Yoshida; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Masatoshi Akamatsu; Ryosuke Tateishi; Tomonori Fujishima; Yujin Hoshida; Miho Kanda; Takashi Ishikawa; Yasushi Shiratori; Masao Omata
Journal:  Hepatol Int       Date:  2007-06       Impact factor: 6.047

Review 4.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

5.  Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection.

Authors:  Noriyuki Miyamoto; Kazuhide Hiramatsu; Kazuhiko Tsuchiya; Yukihiko Sato; Satoshi Terae; Hiroki Shirato
Journal:  Jpn J Radiol       Date:  2009-06-06       Impact factor: 2.374

6.  Histological, CT, and intraoperative ultrasound appearance of hepatic tumors previously treated by laparoscopic radiofrequency ablation.

Authors:  T Mason; E Berber; J C Graybill; A Siperstein
Journal:  J Gastrointest Surg       Date:  2007-07-25       Impact factor: 3.452

Review 7.  Imaging of abdominal nodal spread in malignant disease.

Authors:  S Delorme; G van Kaick
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

8.  Endovascular treatment of primary hepatic tumours.

Authors:  Bogdan Popa; Monica Popiel; Laurenţiu Gulie; Claudiu Turculeţ; Mircea Beuran
Journal:  J Med Life       Date:  2008 Oct-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.